Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease

Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease

A 44-year-old Japanese woman with autosomal dominant polycystic kidney disease was admitted to our hospital for evaluation of abdominal distension. Her eGFR was 53.7 mL/min/1.73 m2. Total kidney volume was 2,614 mL. Tolvaptan (60 mg/day) was started to treat renal involvement. The patient’s abdomina...

Full description

Bibliographic Details
Main Authors: Hiroki Mizuno, Junichi Hoshino, Tatsuya Suwabe, Keiichi Sumida, Akinari Sekine, Yoichi Oshima, Masahiko Oguro, Kyohei Kunizawa, Masahiro Kawada, Rikako Hiramatsu, Noriko Hayami, Eiko Hasegawa, Masayuki Yamanouchi, Naoki Sawa, Kenmei Takaichi, Yoshifumi Ubara
Format: Article
Language:English
Published: Karger Publishers 2017-07-01
Series:Case Reports in Nephrology and Dialysis
Subjects:
Tolvaptan
Autosomal dominant polycystic kidney disease
Polycystic liver disease
Online Access:http://www.karger.com/Article/FullText/477664

Internet

http://www.karger.com/Article/FullText/477664

Similar Items